Andreas Struengmann is a German entrepreneur and investor who, along with his twin brother Thomas, sold their generic drug maker Hexal AG and 68% stake in Eon Labs to Novartis for $7.5 billion in 2005. Since then, they have invested in biotechnology and pharmaceutical companies, as well as a private bank, Sudwestbank. In 2008, they established a neuroscience research center in Frankfurt in honor of their father, Ernst Struengmann. Andreas studied medicine in Freiburg, Germany and worked as a doctor in South Africa. In his free time, he enjoys sailing, golf, and skiing.
Andreas Struengmann is a member of Health care
Age, Biography and Wiki
| Birth Place |
Tegernsee, Germany, Germany |
💰 Net worth: $11.5 Billion (2024)
Andreas Struengmann, a prominent figure in the German health care industry, is currently estimated to have a remarkable net worth of $11.5 billion as of 2024. With a deep-rooted passion for health care, Struengmann has made significant contributions to the industry, cementing his position as one of the most influential figures in Germany. His wealth can be attributed to his successful ventures and investments in various health care businesses. Struengmann's remarkable accomplishments not only demonstrate his entrepreneurial acumen but also highlight his dedication to improving the health care sector in Germany and beyond.
